NOVOCART 3D

Phase 3Cell therapy

AAesculap Biologics, LLC

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Articular CartilageActive, not recruiting

Articular CartilagePhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Articular Cartilage

NCT01957722

Clinical

Trials by Indication[1]

Pediatric Patients2 trials

Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients

Active, not recruiting·TTetec AG··NCT04186208·42 enrolled

Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee

Withdrawn·TTetec AG··NCT05391841

Articular Cartilage1 trial

NOVOCART®3D for Treatment of Articular Cartilage of the Knee

Active, not recruiting·AAesculap Biologics, LLC·Phase 3·NCT01957722·233 enrolled

Knee Cartilage Defects1 trial

Phase III Study to Evaluate Safety and Effectiveness of NOVOCART 3D Plus vs. Microfracture in Knee Cartilage Defects

Completed·TTetec AG·Phase 3·NCT01656902·263 enrolled

Degenerative Disc Disease1 trial

Safety and Efficacy With NOVOCART® Disc Plus (ADCT) for the Treatment of Degenerative Disc Disease in Lumbar Spine

Completed·TTetec AG·Phase 1/2·NCT01640457·120 enrolled

Safety and Efficacy1 trial

Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects

Completed·TTetec AG··NCT02348697·81 enrolled

1 more indication

CAR1 trial

NOVOCART® Inject Plus for Cartilage Defects of the Knee

Completed·TTetec AG·Phase 3·NCT03319797·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NOVOCART 3D. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NOVOCART 3D compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NOVOCART 3D. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aesculap Biologics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: AAesculap Biologics, LLC